Compare Emerson Electric Co. (EMR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs BIO-TECHNE Corp — how do they compare? Emerson Electric Co. trades at $163.95 (market cap $88.53B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Emerson Electric Co. is far larger — about 7.9× BIO-TECHNE Corp's market cap, and Emerson Electric Co. pays the higher dividend (1.4%). Which is the better fit depends on your goals.
| EMR | TECH | |
|---|---|---|
Market Cap | $88.53B | $11.24B |
Sector | Industrials | Health |
52-Week High | $162.47 | $72.29 |
52-Week Low | $123.30 | $43.31 |
Enterprise Value | $99.60B | $11.32B |
Dividend Yield | 1.4% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $158.26, up 0.86% on the day, with a bullish technical signal and strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows robust fundamentals, including a 13.83% net income margin and consistent revenue growth, supported by recent acquisitions like Glue Inc. to enhance AI capabilities. Analyst consensus is positive, with a $171.33 price target indicating potential upside from current levels.
Outlook remains favorable due to organic growth and raised 2026 guidance, but risks include valuation concerns with a P/E of 34.63 and macroeconomic pressures. Investment opportunity hinges on execution in automation and AI segments, while investors should monitor debt levels and competitive dynamics in the industrial sector.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
